Suppr超能文献

利奈唑胺在同情用药项目中治疗患者的群体药代动力学。

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.

作者信息

Meagher Alison K, Forrest Alan, Rayner Craig R, Birmingham Mary C, Schentag Jerome J

机构信息

CPL Associates, LLC, Amherst, New York, USA.

出版信息

Antimicrob Agents Chemother. 2003 Feb;47(2):548-53. doi: 10.1128/AAC.47.2.548-553.2003.

Abstract

Data obtained from 318 adult patients treated under the linezolid compassionate-use protocol were used to develop a population model of the pharmacokinetics of intravenous and oral linezolid. All of the patients received 600 mg of linezolid every 12 h, intravenously and/or orally. Blood samples (2 to 10 per patient; median, 4) were obtained and assayed for linezolid by high-performance liquid chromatography. These data and patient covariates were modeled by iterative two-stage analysis, and model discrimination was done by Akaike's information criterion. Of the patient covariates considered (age, sex, ideal body weight, baseline serum albumin, hepatic or renal dysfunction, underlying malignancy, organ transplantation, surgical status, global severity of illness, site of infection, route of administration, and location of care [intensive-care unit, general floor, or outpatient]), only normalized creatinine clearance (CL(CR)) and body weight explained significant portions of the variance and were incorporated into the pharmacokinetic model. The final model included central and peripheral compartments with parallel capacity-limited (nonrenal) and first-order (renal [CL(R)]) clearances. Volumes and clearances were normalized to the ideal body weight, and CL(R) was modeled as proportional to CL(CR). Compared to previously studied adult volunteers, intrinsic clearance was approximately 60% higher and the maximum rate of metabolism was twice as high in these debilitated patients, resulting in lower area under the time-concentration curve (AUC) values (P < 0.001). The derived 24-h AUC, averaged over the first 7 days of treatment, ranged between 57 and 871 (median, 191) micro g/ml. 24 h. Despite these variations, linezolid provided high rates of clinical cure, as well as microbiological success, in the patients treated in the compassionate-use program. The mechanism(s) of these pharmacokinetic differences is unknown and requires further mechanistic study.

摘要

从318例接受利奈唑胺同情用药方案治疗的成年患者中获取的数据,用于建立静脉注射和口服利奈唑胺的群体药代动力学模型。所有患者每12小时接受600mg利奈唑胺,静脉注射和/或口服。采集血样(每位患者2至10份;中位数为4份),并通过高效液相色谱法测定利奈唑胺。这些数据和患者协变量通过迭代两阶段分析进行建模,模型判别采用赤池信息准则。在考虑的患者协变量中(年龄、性别、理想体重、基线血清白蛋白、肝或肾功能不全、潜在恶性肿瘤、器官移植、手术状态、疾病总体严重程度、感染部位、给药途径和护理地点[重症监护病房、普通病房或门诊]),只有标准化肌酐清除率(CL(CR))和体重解释了大部分变异,并被纳入药代动力学模型。最终模型包括中央室和外周室,具有平行的容量限制(非肾)和一级(肾[CL(R)])清除率。体积和清除率按理想体重进行标准化,CL(R)建模为与CL(CR)成比例。与先前研究的成年志愿者相比,这些虚弱患者的内在清除率高约60%,最大代谢率高两倍,导致时间-浓度曲线下面积(AUC)值较低(P<0.001)。治疗前7天的平均24小时AUC在57至871(中位数为191)μg/ml之间。24小时。尽管存在这些差异,但在同情用药项目中治疗的患者中,利奈唑胺提供了较高的临床治愈率以及微生物学成功率。这些药代动力学差异的机制尚不清楚,需要进一步的机制研究。

相似文献

1
Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.
Antimicrob Agents Chemother. 2003 Feb;47(2):548-53. doi: 10.1128/AAC.47.2.548-553.2003.
2
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.
Clin Pharmacokinet. 2003;42(15):1411-23. doi: 10.2165/00003088-200342150-00007.
3
[Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
Pathol Biol (Paris). 2010 Apr;58(2):e27-31. doi: 10.1016/j.patbio.2009.07.025. Epub 2009 Oct 24.
4
Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.
Antimicrob Agents Chemother. 2011 Jul;55(7):3393-8. doi: 10.1128/AAC.01797-10. Epub 2011 Apr 25.
6
Pharmacokinetics of linezolid in septic patients with and without extended dialysis.
Eur J Clin Pharmacol. 2010 Mar;66(3):291-8. doi: 10.1007/s00228-009-0766-9. Epub 2009 Dec 16.
7
Linezolid clearance during continuous venovenous hemodiafiltration: a case report.
Pharmacotherapy. 2003 Aug;23(8):1071-5. doi: 10.1592/phco.23.8.1071.32874.
8
Linezolid pharmacokinetics in an obese patient.
Am J Health Syst Pharm. 2005 Mar 1;62(5):464, 467. doi: 10.1093/ajhp/62.5.464a.
9
Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.
Int J Antimicrob Agents. 2010 Aug;36(2):179-81. doi: 10.1016/j.ijantimicag.2010.02.019. Epub 2010 Apr 13.
10
Linezolid pharmacokinetics in adult patients with cystic fibrosis.
Antimicrob Agents Chemother. 2004 Jan;48(1):281-4. doi: 10.1128/AAC.48.1.281-284.2004.

引用本文的文献

1
Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis.
J Clin Tuberc Other Mycobact Dis. 2024 Jul 27;37:100470. doi: 10.1016/j.jctube.2024.100470. eCollection 2024 Dec.
4
The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection.
Microbiol Spectr. 2022 Oct 26;10(5):e0245121. doi: 10.1128/spectrum.02451-21. Epub 2022 Sep 15.
5
A Review of Population Pharmacokinetic Analyses of Linezolid.
Clin Pharmacokinet. 2022 Jun;61(6):789-817. doi: 10.1007/s40262-022-01125-2. Epub 2022 Jun 14.
8
Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0138121. doi: 10.1128/AAC.01381-21. Epub 2021 Sep 20.
10
Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
Infect Chemother. 2021 Sep;53(3):503-511. doi: 10.3947/ic.2021.0034. Epub 2021 Jul 28.

本文引用的文献

3
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
6
Prediction of creatinine clearance from serum creatinine.
Nephron. 1976;16(1):31-41. doi: 10.1159/000180580.
7
A program package for simulation and parameter estimation in pharmacokinetic systems.
Comput Programs Biomed. 1979 Mar;9(2):115-34. doi: 10.1016/0010-468x(79)90025-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验